spisulosine
from marine organism, Spisula polynyma; structure in first source
Also Known As:
1-deoxysphinganine; ES 285; ES-285; ES285; doxSA cpd; 3-Octadecanol, 2-amino-, (2S,3R)-
Networked: 12
relevant articles (1 outcomes,
5 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Garcia-Barros, Monica:
1 article
(01/2022)
|
2. | Hannun, Yusuf A:
1 article
(01/2022)
|
3. | Mao, Cungui:
1 article
(01/2022)
|
4. | Mileva, Izolda:
1 article
(01/2022)
|
5. | Montal, Emily:
1 article
(01/2022)
|
6. | Obeid, Lina M:
1 article
(01/2022)
|
7. | Ruiz, Christian F:
1 article
(01/2022)
|
8. | Snider, Ashley J:
1 article
(01/2022)
|
9. | Truman, Jean-Philip:
1 article
(01/2022)
|
10. | Dai, Rongyang:
1 article
(03/2021)
|
Related Diseases
1. | Neoplasms (Cancer)
06/01/2009
- " A dose-escalation, phase I study evaluated the safety, pharmacokinetics, pharmacogenomics, and efficacy of ES-285, a novel agent isolated from a marine mollusc, in adult cancer patients. " 12/01/2012
- " This phase I clinical trial was designed to identify the maximum tolerated dose (MTD) and the recommended dose for phase II trials (RD), as well as to evaluate the safety profile, pharmacokinetics and preliminary efficacy data of ES-285 in patients with advanced solid tumors. " 02/15/2020
- " New Spisulosine Derivative promotes robust autophagic response to cancer cells." 04/28/2008
- " In the present work, we studied the mechanism of action of a new compound, Spisulosine (ES-285), isolated from the sea mollusc Spisula polynyma, in the prostate tumor PC-3 and LNCaP cell lines. " 12/01/2012
- " Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors."
|
2. | Disease Progression
|
3. | Reperfusion Injury
|
4. | Starvation
|
5. | Hereditary Sensory and Autonomic Neuropathies (HSAN)
|
|
Related Drugs and Biologics
Related Therapies and Procedures